A novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma
Abstract Background A growing body of evidence suggests that pyroptosis-related lncRNAs (PRncRNAs) are associated with the prognoses of tumor patients and their tumor immune microenvironments. However, the function of PRlncRNAs in lung squamous cell carcinoma (LUSC) remains unclear. Methods We downl...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-06-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-022-09790-z |
| _version_ | 1811229967231483904 |
|---|---|
| author | Wei Zhou Wenxiong Zhang |
| author_facet | Wei Zhou Wenxiong Zhang |
| author_sort | Wei Zhou |
| collection | DOAJ |
| description | Abstract Background A growing body of evidence suggests that pyroptosis-related lncRNAs (PRncRNAs) are associated with the prognoses of tumor patients and their tumor immune microenvironments. However, the function of PRlncRNAs in lung squamous cell carcinoma (LUSC) remains unclear. Methods We downloaded the transcriptome and clinical information of 551 LUSC samples from the The Cancer Genome Atlas (TCGA) database and randomly separated patients with complete information into two cohorts. Based on the training cohort, we developed a pyroptosis-related signature. We then examined the signature in the test cohort and all retained patients. We also clustered two risk groups in each cohort according to the signature and performed survival analysis, functional analysis, tumor immune microenvironment analysis and drug sensitivity analysis. Results A prognostic signature containing five PRlncRNAs (AP001189.1, PICART1, LINC02555, AC010422.4, and AL606469.1) was developed. A principal component analysis (PCA) indicated better differentiation between patients with different risk scores. Kaplan–Meier (K–M) analysis demonstrated poorer survival among patients with higher risk scores (P < 0.001). A receiver operating characteristic (ROC) curve analysis provided evidence confirming the accuracy of the signature, and univariate (p = 0.005) and multivariate (p = 0.008) Cox regression analyses confirmed the independent value of the risk score in prognoses. Clinical subgroup validation indicated that the signature was more suitable for patients with early-stage LUSC. We also created a nomogram to increase the accuracy of the prediction. Moreover, functional analysis revealed that pathways related to tumor development and pyroptosis were enriched in the high-risk group. Furthermore, the prognostic signature was proven to be a predictor of sensitivity to immunotherapy and chemotherapy. Conclusions We developed a novel pyroptosis-associated signature with independent value for the prognosis of LUSC patients. PRlncRNAs are closely associated with the tumor immune microenvironment in LUSC and might offer new directions for immunotherapy. |
| first_indexed | 2024-04-12T10:22:11Z |
| format | Article |
| id | doaj.art-0971a45c356c4d31a23e1b57421a05f1 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-12T10:22:11Z |
| publishDate | 2022-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-0971a45c356c4d31a23e1b57421a05f12022-12-22T03:37:04ZengBMCBMC Cancer1471-24072022-06-0122111310.1186/s12885-022-09790-zA novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinomaWei Zhou0Wenxiong Zhang1Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang UniversityDepartment of Thoracic Surgery, The Second Affiliated Hospital of Nanchang UniversityAbstract Background A growing body of evidence suggests that pyroptosis-related lncRNAs (PRncRNAs) are associated with the prognoses of tumor patients and their tumor immune microenvironments. However, the function of PRlncRNAs in lung squamous cell carcinoma (LUSC) remains unclear. Methods We downloaded the transcriptome and clinical information of 551 LUSC samples from the The Cancer Genome Atlas (TCGA) database and randomly separated patients with complete information into two cohorts. Based on the training cohort, we developed a pyroptosis-related signature. We then examined the signature in the test cohort and all retained patients. We also clustered two risk groups in each cohort according to the signature and performed survival analysis, functional analysis, tumor immune microenvironment analysis and drug sensitivity analysis. Results A prognostic signature containing five PRlncRNAs (AP001189.1, PICART1, LINC02555, AC010422.4, and AL606469.1) was developed. A principal component analysis (PCA) indicated better differentiation between patients with different risk scores. Kaplan–Meier (K–M) analysis demonstrated poorer survival among patients with higher risk scores (P < 0.001). A receiver operating characteristic (ROC) curve analysis provided evidence confirming the accuracy of the signature, and univariate (p = 0.005) and multivariate (p = 0.008) Cox regression analyses confirmed the independent value of the risk score in prognoses. Clinical subgroup validation indicated that the signature was more suitable for patients with early-stage LUSC. We also created a nomogram to increase the accuracy of the prediction. Moreover, functional analysis revealed that pathways related to tumor development and pyroptosis were enriched in the high-risk group. Furthermore, the prognostic signature was proven to be a predictor of sensitivity to immunotherapy and chemotherapy. Conclusions We developed a novel pyroptosis-associated signature with independent value for the prognosis of LUSC patients. PRlncRNAs are closely associated with the tumor immune microenvironment in LUSC and might offer new directions for immunotherapy.https://doi.org/10.1186/s12885-022-09790-zLung squamous cell carcinomaPyroptosisLong non-coding RNAPrognostic signatureImmunotherapy |
| spellingShingle | Wei Zhou Wenxiong Zhang A novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma BMC Cancer Lung squamous cell carcinoma Pyroptosis Long non-coding RNA Prognostic signature Immunotherapy |
| title | A novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma |
| title_full | A novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma |
| title_fullStr | A novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma |
| title_full_unstemmed | A novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma |
| title_short | A novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma |
| title_sort | novel pyroptosis related lncrna prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma |
| topic | Lung squamous cell carcinoma Pyroptosis Long non-coding RNA Prognostic signature Immunotherapy |
| url | https://doi.org/10.1186/s12885-022-09790-z |
| work_keys_str_mv | AT weizhou anovelpyroptosisrelatedlncrnaprognosticsignatureassociatedwiththeimmunemicroenvironmentinlungsquamouscellcarcinoma AT wenxiongzhang anovelpyroptosisrelatedlncrnaprognosticsignatureassociatedwiththeimmunemicroenvironmentinlungsquamouscellcarcinoma AT weizhou novelpyroptosisrelatedlncrnaprognosticsignatureassociatedwiththeimmunemicroenvironmentinlungsquamouscellcarcinoma AT wenxiongzhang novelpyroptosisrelatedlncrnaprognosticsignatureassociatedwiththeimmunemicroenvironmentinlungsquamouscellcarcinoma |